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Tuberculosis comorbidity with communicable and 
non-communicable diseases: integrating health services 
and control eﬀ orts
Ben J Marais, Knut Lönnroth, Stephen D Lawn, Giovanni Battista Migliori, Peter Mwaba, Philippe Glaziou, Matthew Bates, Ruth Colagiuri, 
Lynn Zijenah, Soumya Swaminathan, Ziad A Memish, Michel Pletschette, Michael Hoelscher, Ibrahim Abubakar, Rumina Hasan, Aﬁ a Zafar, 
Guiseppe Pantaleo, Gill Craig, Peter Kim, Markus Maeurer, Marco Schito, Alimuddin Zumla
Recent data for the global burden of disease reﬂ ect major demographic and lifestyle changes, leading to a rise in non-
communicable diseases. Most countries with high levels of tuberculosis face a large comorbidity burden from both 
non-communicable and communicable diseases. Traditional disease-speciﬁ c approaches typically fail to recognise 
common features and potential synergies in integration of care, management, and control of non-communicable and 
communicable diseases. In resource-limited countries, the need to tackle a broader range of overlapping comorbid 
diseases is growing. Tuberculosis and HIV/AIDS persist as global emergencies. The lethal interaction between 
tuberculosis and HIV coinfection in adults, children, and pregnant women in sub-Saharan Africa exempliﬁ es the 
need for well integrated approaches to disease management and control. Furthermore, links between diabetes 
mellitus, smoking, alcoholism, chronic lung diseases, cancer, immunosuppressive treatment, malnutrition, and 
tuberculosis are well recognised. Here, we focus on interactions, synergies, and challenges of integration of 
tuberculosis care with management strategies for non-communicable and communicable diseases without eroding 
the functionality of existing national programmes for tuberculosis. The need for sustained and increased funding for 
these initiatives is greater than ever and requires increased political and funder commitment.
Introduction
In recent decades, the prevalence of non-com municable 
diseases has risen, an increase attributable to historic and 
projected demographic shifts of the world’s population, 
together with urbanisation and accom panying lifestyle 
changes.1 Countries of low and middle income now have a 
large burden of non-communicable disease, which 
overlaps with the unﬁ nished agenda of communicable 
diseases; the risk factors of poverty, unhealthy lifestyles, 
tobacco use, and alcohol misuse are common to both 
categories of disease.2–6 People living with chronic 
communicable diseases such as tuber culosis and HIV/
AIDS are most likely to develop comorbidity with non-
communicable diseases. More over, coexisting com-
municable and non-communicable diseases augment the 
risk or eﬀ ect of the other. Health-care systems in resource-
limited settings are poorly equipped to deal with this 
double burden of disease,7 and disease-speciﬁ c health-care 
approaches do not represent the most eﬃ  cient response.8,9 
Therefore, traditional approaches to global health need to 
be reassessed, with greater emphasis on multidisciplinary 
collaboration and integrated strategies.
In the 2010 Global Burden of Disease study,2–4 the 
number of deaths per year (1980–2010) from 235 causes 
were estimated for 187 countries. In 2010, 52·8 million 
deaths were recorded worldwide, of which 24·9% 
were attributable to communicable diseases related to 
maternal, neonatal, and nutritional causes, a fall from 
34·1% of 46·5 million deaths in 1990.3 These data 
show a continued shift from communicable to 
non-communicable diseases and from premature 
deaths to years lived with disability. However, disease 
projections that reﬂ ect ever decreasing rates of 
communicable diseases fail to appreciate their highly 
dynamic and unpredictable nature. Globalisation, 
increased popu la tion density, and environmental dis-
ruption present a fertile ground for emergence of new 
com municable diseases.10 Movement of people and 
growing drug resistance are important factors 
hampering global tuberculosis control eﬀ orts.11–15
In sub-Saharan Africa, communicable diseases and 
maternal, neonatal, and nutritional disorders remain the 
dominant causes of disease burden.3,4 Deaths from HIV/
AIDS increased from 0·30 million in 1990 to 1·5 million 
in 2010, and malaria mortality rose by an estimated 
19·9% since 1990, to 1·17 million deaths in 2010. WHO 
estimates show that, in 2011, 8·7 million new cases of 
tuberculosis were recorded and 1·4 million people died 
from the disease, including 350 000 deaths associated 
with HIV coinfection.16 Sub-Saharan Africa, India, and 
China have the highest number of tuberculosis cases,16 
and multidrug-resistant tuberculosis has become 
widespread in eastern Europe.17
Here, we focus on the close relationship between 
tuberculosis and non-communicable disease, and 
tuberculosis and other communicable diseases, in 
terms of comorbidity, causation, and health care. We 
also investigate commonalities, synergies, and chal-
lenges for integration of tuberculosis care and control 
eﬀ orts and make proposals for change.
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Factors aﬀ ecting comorbidity
Identiﬁ cation of the best strategies for prevention and 
management of overlapping disease burdens supports 
progress towards attainment of the Millennium 
Develop mental Goals (MDGs). For example, after 
correction for health system variables, lower burdens of 
non-commu nicable diseases and HIV infection were 
associated with much greater progress towards 
MDG goals for child mortality and tuberculosis 
than were gains in gross domestic product.18 Although 
social determinants of health are the main factors that 
drive the current tuberculosis pandemic,19,20 other 
risk factors for Mycobacterium tuberculosis infection and 
progression to active tuber culosis disease are well 
known (panel 1). Figure 1 shows the geographical 
variation in burden of tuberculosis and associated 
comorbidities.
HIV-associated tuberculosis
Tuberculosis and HIV/AIDS are both chronic diseases 
and continue as global emergencies. Tuberculosis is a 
leading cause of death in people coinfected with HIV.16 
The lethal bidirectional interaction between these two 
diseases in sub-Saharan Africa exempliﬁ es the need for 
well integrated approaches to disease identiﬁ cation, 
management, and control. HIV infection increases the 
risk of tuberculosis by 20–40-fold, and tuberculosis 
accounts for 25% of HIV-related deaths worldwide—the 
single biggest cause.16 The HIV epidemic fuelled the 
threefold to ﬁ vefold rise in tuberculosis notiﬁ cation rates 
between 1990 and 2005 in sub-Saharan Africa, which 
bears 80% of the global burden of HIV-associated 
tuberculosis. Thus, health systems are generally weakest 
where the disease burden is greatest. In the mid-1990s, 
early application of WHO’s global DOTS (directly 
observed treatment, short-course) strategy, without 
explicit tuberculosis–HIV collaborative activities, proved 
inadequate to stem the tuberculosis epidemic in settings 
with a high prevalence of HIV.21
WHO published a comprehensive three-pronged 
strategy for collaborative tuberculosis–HIV activities in 
2004, which was updated in 2012.21,22 First, mechanisms 
for delivery of integrated tuberculosis and HIV services 
need to be established and strengthened at all levels of 
the health service. Second, the burden of tuberculosis in 
people living with HIV needs to be reduced by 
implementation of early combination anti retroviral 
therapy together with isoniazid preventive therapy, 
intensiﬁ ed case-ﬁ nding, and improved infection control. 
Third, the burden of HIV in patients with suspected or 
diagnosed tuberculosis needs to be reduced through 
provider-initiated HIV testing and counselling, HIV 
prevention services for those who test negative, and 
optimised case management for those who test positive.
Young children from HIV-aﬀ ected households are at 
high risk of tuberculosis exposure.23 Tuberculosis 
remains a major unrecognised cause of death in young 
children—both HIV-infected and HIV-uninfected—in 
endemic areas.24,25 Young children are also at risk of HIV 
infection through the infected mother.26 Active screening 
of household contacts to rule out tuberculosis and 
provide preventive treatment to vulnerable individuals, 
particularly young children, could be linked to active 
HIV case-ﬁ nding by simple point-of-care testing.26 Close 
links with maternal and child health programmes are 
essential to ensure universal tuberculosis and HIV 
screening of pregnant mothers, implementation of 
eﬀ ective strategies to prevent mother-to-child HIV trans-
mission, and early initiation of combined antiretroviral 
therapy in all HIV-infected infants.27
Adverse drug reactions complicate concurrent 
treatment of HIV/AIDS and tuberculosis.27 Although 
efavirenz-based combined antiretroviral regi mens can be 
used with standard tuberculosis drugs, use of protease 
inhibitors with rifampicin is problematic because 
rifampicin signiﬁ cantly reduces con centrations in serum 
of protease inhibitors; use of dose-adjusted lopinavir and 
ritonavir with rifampicin, or substitution of rifampicin 
with rifabutin, is needed.28 Study ﬁ ndings show that early 
initiation of combined antiretroviral therapy in people 
with low CD4+ T-cell counts reduces mortality and 
Key messages
• Comorbidity of tuberculosis with non-communicable 
diseases (eg, diabetes mellitus, malnutrition, 
smoking-related and alcohol-related diseases) and other 
communicable diseases (eg, HIV/AIDS) is prevalent in 
regions of the world that are highly endemic for 
tuberculosis; integrated and eﬃ  cient responses are required 
to tackle these comorbidities in resource-poor countries
• Wider integration of tuberculosis control activities presents 
opportunities to investigate commonalities and potential 
synergies in management and control of communicable 
and non-communicable diseases, which have been 
overlooked by traditional vertical approaches, without 
sacriﬁ cing recent gains in health care or eroding the 
functionality of existing programmes
• Early initiation of antiretroviral therapy should be a priority 
for HIV-infected individuals with newly diagnosed 
tuberculosis; bidirectional screening for diabetes mellitus 
and tuberculosis is needed
• Levels of unsuspected comorbidity are high; patients with 
concurrent communicable or non-communicable diseases, 
or pregnant women attending antenatal clinics who have 
concurrent active or subclinical tuberculosis, are frequently 
overlooked
• Eﬃ  cient integration of tuberculosis services should be 
encouraged while maintaining some vertical elements to 
secure essential functions, such as drug supply, monitoring, 
assessment, and national surveillance, to a point at which 
the national tuberculosis programme could be restricted to 
a small central team doing general oversight
438 www.thelancet.com/infection   Vol 13   May 2013
Series
AIDS-deﬁ ning disorders.29–31 Thus, WHO recommends 
such regimens should be started as soon as possible and 
within the ﬁ rst 8 weeks of tuberculosis treatment 
initiation.32 This recommen dation requires a patient-
centred approach tailored to national and local health 
infrastructure, such that patients with HIV-associated 
tuberculosis can receive treatment for both diseases at 
the same health facility, either in diﬀ erent clinics or in 
the same clinic but always in a coordinated and integrated 
manner. Furthermore, in a systematic review33 of studies 
looking at the eﬀ ect of combined antiretroviral therapy 
on the incidence of tuberculosis in adults with HIV 
infection, combined regimens were associated strongly 
with a reduction in the incidence of tuberculosis across 
all CD4+ T-cell strata, and early initiation of combined 
antiretroviral therapy was proposed as a key component 
of national strategies to control HIV-associated 
tuberculosis.
Social determinants of tuberculosis
• Poverty
• Stress
• Poor housing
• Poor ventilation (domestic and workplace)
• Crowded living conditions (eg, prisons, refugee camps, 
homeless shelters, mass gatherings, shanty compounds)
• Malnutrition
• Alcohol or substance misuse
• Air pollution (eg, biomass fuels, cigarette smoke) 
• Extremes of age: very old and very young people
• Pregnancy and childbirth
• Travel to a country highly endemic for tuberculosis
Risk factors for development of active tuberculosis
• HIV
• Diabetes mellitus
• Poor nutrition
• Chronic lung disease
• Chronic obstructive pulmonary disease
• Silicosis
• Active smoking
• Alcohol
• Substance (drug) misuse
• Immunosuppressive treatment
• Contact with a person with active pulmonary tuberculosis
• Genetic factors
• Congenital immunodeﬁ ciencies (eg, chronic granulomatous 
disease, common variable immunodeﬁ ciency)
Clinically observed associations with tuberculosis
Patients with communicable diseases
• HIV/AIDS
• Sexually transmitted infections
• Viral hepatitis
• Bacterial, viral, fungal pneumonias
• Empyema
• Helminth infestations
Patients with non-communicable diseases
• Diabetes mellitus
• Chronic lung diseases (eg, emphysema, chronic bronchitis, 
silicosis)
• Chronic kidney disease or end-stage renal failure
• Autoimmune hepatitis
• Gut malabsorption syndromes
• Gastric bypass or gastrectomy
• Crohn’s disease
• Ulcerative colitis
• Organ transplants
• Malignant disease (eg, oral, oesophageal, nasopharyngeal, 
lung)
• Reticuloendothelial disorders (eg, leukaemia, Hodgkin’s 
lymphoma, multiple myeloma)
• Rheumatoid arthritis
• Autoimmune diseases
• Psoriasis
• Alopecia areata
• Sarcoidosis
• Solid organ transplants
Micronutrient and vitamin deﬁ ciencies
• Zinc deﬁ ciency
• Vitamin D deﬁ ciency
• Vitamin A deﬁ ciency
Pharmacological treatments that could reactivate latent 
tuberculosis infection
• Immunosuppressants
• Steroids (eg, prednisone, prednisolone, 
methylprednisolone)
• Antimetabolites (eg, methotrexate, azathioprine, 
leﬂ unomide)
• T-cell inhibitors (eg, ciclosporin, tacrolimus)
• Alkylating agents (eg, cyclophosphamide, chlorambucil)
• Biological agents
• Tumour necrosis factor or interleukin 2 blockers 
(eg, etanercept, inﬂ iximab, adalimumab)
• Humanised chimaeric monoclonal antibodies 
(eg, basiliximab, daclizumab, muromonab-CD3, 
tacrolimus)
• Non-steroidal anti-inﬂ ammatory drugs (eg, ibuprofen, 
diclofenac)
Occupation or high-risk work environment
• Miners
• Health-care workers
• Laboratory personnel
• Residential care staﬀ 
• Prison staﬀ 
• Refugee camp workers
Panel 1: Risk factors associated with Mycobacterium tuberculosis infection and progression to active tuberculosis disease
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Millions of HIV-infected people are at risk of com-
municable lung diseases. In view of the eﬀ ectiveness of 
modern combined antiretroviral therapy regimens, HIV 
infection has become a chronic illness. Non-
communicable diseases aﬀ ecting the lung (such as 
chronic obstructive pulmonary disease [COPD]) and 
metabolic disorders (such as diabetes mellitus) are on 
the rise. Increasingly, the health-care needs of people on 
combined antiretroviral drugs resemble those of 
individuals with chronic non-communicable disorders. 
Since vertical programmes are diﬃ  cult to sustain when 
health systems are under-resourced and strained, calls 
have been made to focus care at the primary level for 
people with chronic diseases.34
Tuberculosis and non-communicable diseases
Non-communicable diseases were not included explicitly 
during formulation of the MDGs. This oversight was 
partly corrected when the UN published a declaration on 
the prevention and control of non-communicable 
diseases,1 which was supported by all 193 member states. 
Despite intercountry heterogeneity resulting from 
variable demographic and socioeconomic transition, 
most non-communicable and communicable diseases 
are associated with a strong social gradient, mostly 
aﬀ ecting poor and marginalised populations.
Historically, eﬀ orts to control communicable and non-
communicable diseases had little in common and tended 
to emphasise diﬀ erences rather than similarities.8 
However, despite being transmissible, management and 
control of chronic infectious diseases such as tuber-
culosis has more in common with non-communicable 
diseases than with acute communicable diseases (table). 
Synergies that could be investigated in public health 
eﬀ orts include joint health promotion strategies and 
reciprocal screening and coordinated management 
programmes (panel 2). Non-communicable diseases 
interact adversely with tuberculosis by increasing both 
individual vulnerability to disease and the likelihood that 
the epidemic will be sustained within a population.35 
Individual vulnerability is aﬀ ected by the number and 
severity of comorbid disorders, whereas the total burden 
of comorbidity determines vulnerability at the population 
level.
Diabetes mellitus and tuberculosis
The link between diabetes mellitus and tuberculosis 
has long been recognised, but the looming threat of 
these convergent global epidemics has only recently 
been appreciated.35–39 Study ﬁ ndings consistently show 
a twofold to threefold higher risk of developing 
tuberculosis in patients with diabetes mellitus 
Incidence of 
tuberculosis 
per 100 000 
population
 0–19
 20–49
 50–99
 100–199
 ≥200
A B
C D
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Figure 1: Worldwide incidence of tuberculosis, prevalence of HIV and diabetes in adults, and deaths from COPD in boys and men
(A) Estimated incidence of tuberculosis per 100 000 population in 2011. Data sourced from reference 16. (B) Prevalence of HIV in people age 15–49 years in 2011. (C) Prevalence of adults age 25 years 
or older with blood glucose greater than 7 mmol/L in 2008. (D) COPD mortality per 100 000 boys and men in 2008. Data for B–D sourced from WHO’s Global Health Observatory (accessed 
Nov 20, 2012). COPD=chronic obstructive pulmonary disease.
For WHO’s Global Health 
Observatory see http://www.
who.int/gho/en
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compared with people without diabetes. However, the 
prevalence of diabetes mellitus among patients with 
tuberculosis varies according to the setting,40,41 possibly 
attributable to diﬀ erences in background prevalence of 
diabetes mellitus between populations and alternative 
clinical and labora tory methods of screening and 
diagnosing diabetes mellitus. In India, an estimated 
2·2 million cases of tuberculosis are recorded per year 
and about 60 million people have diabetes mellitus; 
14·8% of the tuberculosis burden has been attributed to 
diabetes mellitus.39 In a study from the Indian state of 
Tamil Nadu, nearly 50% of patients with tuberculosis 
had either diabetes mellitus (25·3%) or prediabetes 
(24·5%).39 In a Chinese survey of 8886 registered 
tuberculosis cases, 1090 (12·4%) patients had diabetes 
mellitus and 575 (7·8%) had impaired fasting 
glucose.40,41 Prevalence of diabetes mellitus was 
signiﬁ cantly higher in patients with tuber culosis in 
urban areas (14·0%) versus rural populations (10·6%), 
and it was higher among people with tuberculosis than 
in the general population in both urban and rural areas. 
Africa also has rising rates of diabetes mellitus, 
particularly in urban populations.42,43 In Zambia, 
unsuspected tuberculosis among adult inpatients was 
signiﬁ cantly associated with diabetes mellitus (odds 
ratio 6·6, 95% CI 1·7–25·3).44 In Hispanic populations 
in the USA, diabetes mellitus has long been recognised 
as a factor contributing to high prevalence of 
tuberculosis.45 People with diabetes also show impaired 
sputum conversion and cure rates on tuberculosis 
treatment, with increased risk of death and relapse.46–48
To address the double burden of tuberculosis and 
diabetes mellitus and the absence of international 
guidelines, WHO and the International Union Against 
Tuberculosis and Lung Disease developed a collaborative 
framework for care and control of these diseases,49 which 
sets outs out principles for bidirectional screening and 
coordinated management of the two diseases. The 
framework is based on data from systematic reviews on 
the diagnosis and management of diabetes and tuber-
culosis. Similarly, the International Diabetes Federation 
recognises the link between communicable and non-
communicable dis eases and supports the reorientation 
and integration of the health workforce and services to 
simultaneously address this double burden of disease.50 
An important limitation of dual screening for tuberculosis 
in patients with diabetes mellitus, and vice versa, is cost-
eﬀ ective ness. WHO recommends screening for 
tuberculosis only if the estimated prevalence of the disease 
in the population is more than 100 cases per 
100 000 population, which implies screening around 
100 people to detect one case of tuberculosis. However, 
good examples of integration of diabetes mellitus and 
tuberculosis screening come from China.40,41
Risk of metabolic disease is increased in HIV-infected 
patients on lifelong combined antiretroviral therapy. In 
one study,51 the incidence of diabetes rose with 
cumulative exposure to combined antiretroviral 
therapy, and stavudine and zidovudine were 
signiﬁ cantly associated with diabetes risk. In a 
prospective study,52 use of a protease inhibitor was 
associated with a threefold increased risk of incident 
diabetes mellitus. This ﬁ nding is a particular concern 
in sub-Saharan Africa, where ﬁ rst-line antiretroviral 
therapy typically uses lower cost drugs that often have 
more metabolic complications.42 Even with increased 
availability of cheaper, less toxic, generic ﬁ xed-drug 
Communicable diseases Non-communicable 
diseases (eg, diabetes, 
COPD, coronary artery 
disease, cancer, chronic 
renal failure)
Acute (eg, inﬂ uenza, 
meningococcal 
meningitis, bacterial 
pneumonia, malaria)
Chronic (eg, tuberculosis, 
HIV, leprosy, syphilis, 
leishmaniasis, 
schistosomiasis)
Transmission Possible Possible Not possible
Infection control Important Important No issues
Prevention Necessary Necessary Necessary
Point-of-care testing Limited Available for HIV Common
Cure Mostly curable or 
transient
Mostly curable Rarely curable
Management Short-term treatment Long-term management Long-term management
Problems with 
treatment adherence
Limited Major Major
Change to lifestyle None required Required Required
Case management Mostly triage at primary 
health-care level, 
management of severe 
cases at referral centres
Most cases managed at 
primary health-care level
Most cases managed at 
primary health-care level
COPD=chronic obstructive pulmonary disease.
Table: Diﬀ erences and similarities between communicable and non-communicable diseases
Panel 2: Potential synergies and advantages of integrated 
health care
Best care for patients
• Consolidates continuity of care
• Avoids multiple clinic attendances
Optimum use of available resources
• Combined and coordinated human resource 
development and training activities
• Cross-utilisation of health-care workers and multiskilling
• Reciprocal screening programmes
• Combined infrastructure development
• Integrated recording and reporting systems
Combined prevention strategies
• Poverty alleviation
• Creation of an environment that sustains health and 
wellbeing
• Health messaging and communication
• Community and user education and enga gement
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combinations, zidovudine remains an important 
component of ﬁ rst-line combined antiretro viral 
treatment, and lopinavir and ritonavir are vital 
components of second-line regimens worldwide. HIV-
infected patients in resource-limited settings are at 
high risk of developing metabolic abnormalities, with 
sub optimum assessment for and management of 
potential long-term complications.
Malnutrition
Countries in epidemiological transition are aﬀ ected 
adversely by both overnutrition and undernutrition. 
An individual who is either moderately to severely 
underweight or micronutrient-deﬁ cient is at increased 
vulnerability to develop tuberculosis,53–56 although 
evidence for the detrimental eﬀ ect of milder nutrient 
deﬁ ciencies is less robust. A reanalysis was done of US 
National Health and Nutrition Examination Survey data 
gathered in 1971–75 and matched to tuberculosis 
outcomes in 1982–92.57 Disease rates of 24·7 per 
100 000 person-years (95% CI 13·0–36·3) were recorded 
in normal-weight individuals. After controlling for 
demographic, socioeconomic, and medical charac-
teristics, adjusted hazard ratios in people who were 
underweight, over weight, and obese were 12·4 (95% CI 
5·8–27·0), 0·3 (0·1–0·6), and 0·20 (0·1–0·6), 
respectively.57 The fact that malnutrition is very common 
in many parts of the world accounts for its large 
contribution to the attributable risk for tuberculosis. 
The eﬀ ects of malnutrition, notably in utero and in early 
life, also take a major toll in the form of obesity, diabetes 
mellitus, hypertension, and heart disease in later life,57 
thus serving to reinforce the double burden of disease 
in poorer countries and among disadvantaged sub-
populations of wealthier nations.
Rates of malnutrition, anaemia, and micronutrient 
deﬁ ciencies are ampliﬁ ed by chronic worm infestation, 
although the contribution is poorly quantiﬁ ed.58 Worm 
infestation might also increase vulnerability to tuber-
culosis via immune-mediated mechanisms, but the 
exact pathways await better characterisation.59 Excessive 
exposure to mycotoxins (aﬂ atoxins and fumonisins) is a 
particular risk factor in underdeveloped rural areas, 
where food is not stored in temperature-controlled and 
humidity-controlled environments. Fungal contamin-
ation of stored food could result in immunosuppression 
or various systemic adverse eﬀ ects60 that could increase 
tuberculosis vulnerability.
Tobacco, alcohol, and drug dependency and 
tuberculosis
Cigarette smoking, including passive smoking, has been 
associated consistently with an increased risk of 
M tuber culosis infection, subsequent disease develop ment, 
and poor treatment outcomes.61,62 The mechanisms have 
not been elucidated fully, but airway immunity is aﬀ ected 
negatively by cigarette smoke inhalation, and we are only 
starting to appreciate the importance of local immune 
responses within the lung in the pathogenesis of 
tuberculosis.63,64 In China, ﬁ ndings of a multiple risk factor 
modelling study assessing the eﬀ ects of smoking and 
solid-fuel use on COPD, lung cancer, and tuber culosis 
showed that complete gradual cessation of smoking and 
solid-fuel use by 2033 could avoid 26 million deaths from 
COPD and 6·3 million deaths from lung cancer and 
would reduce the projected incidence of tuberculosis in 
2033 by 14–52% if 80% DOTS coverage were sustained.65 
WHO and the Inter national Union Against Tuberculosis 
and Lung Disease have developed a framework for 
coordinated action on tuberculosis and tobacco control.66
Misuse of alcohol and other addictive substances also 
augments the likelihood of developing tuberculosis, 
although separation of its independent eﬀ ect from asso-
ciated malnutrition, other comorbidities, and increased 
tuberculosis exposure is diﬃ  cult within the social con-
text.67,68 Alcohol misuse is associated with poor treatment 
adherence and a signiﬁ cantly ampliﬁ ed risk of relapse and 
death during and after tuberculosis treatment.67,68 
Diagnosis and treatment of harmful drinking and alcohol 
misuse disorders should be part of basic clinical care for 
people with tuberculosis, particularly in settings with high 
alcohol consumption. More research is needed to assess 
the eﬀ ect of such interventions on tuberculosis outcomes.69 
In a review of autopsies done on people who died with 
tuberculosis in London, UK, 35 of 46 cases had 
comorbidities, mainly hepatitis C virus and HIV infections, 
cancer, cardiovascular disease, and COPD.70 Hepatitis C 
infection is especially prevalent in injecting drug users. 
Control measures for tobacco, alcohol, and drug misuse 
are an obvious priority for improved public health.
Chronic lung disease and tuberculosis
Chronic lung disease reﬂ ects the cumulative eﬀ ect of 
multiple lung insults, including inhalation of cigarette 
and solid-fuel smoke, silica, and other air pollutants, and 
allergens, together with recurrent chest infections.71 
Modelling the eﬀ ects of cigarette smoking and solid-fuel 
exposure in China,65 and the well-known comorbidity 
between pulmonary silicosis and tuberculosis,72–74 shows 
how chronic lung disease increases vulnerability to 
tuberculosis, and the cycle is mutually reinforcing.75 
Tuberculosis, COPD, and smoking have major impli-
cations for global lung health.73 Chronic lung disease74 
accounts for some of the substantial diﬀ erences in 
life expectancy noted within Europe, emphasising the 
importance of integrated lung health initiatives such as 
the practical approach to lung health (PAL)75 and the 
European respiratory roadmap.76
Concomitant tuberculosis in 
immunocompromised people
Tuberculosis is seen increasingly in patients with medical 
conditions and those who are receiving treat ment that 
compromises the immune system.77–81 WHO estimates 
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that nearly 2 billion people globally have latent 
M tuberculosis infection,79 and these individuals are at risk 
of developing active tuberculosis disease when the body’s 
immune system is perturbed. Apart from immuno-
suppression due to HIV, any immunocomprom ised state 
increases susceptibility to either development of active 
tuberculosis after infection or reactivation of latent 
infection. These include physiological (very young and 
elderly people), pathological (malignant dis ease), 
therapeutic (immunosuppressive treatment), and 
chronic disease states (panel 1). Targeted biological 
agents that block tumour necrosis factor α have trans-
formed treatment of chronic inﬂ ammatory, rheumato-
logical, and autoimmune diseases. However, reactivation 
of latent M tuberculosis infection in patients using these 
drugs is leading increasingly to comorbidity of active 
tuberculosis and non-commu nicable diseases.78 Although 
this occurrence is not a major public health issue, it has 
important implications for management of individual 
patients in countries with low endemicity for tuberculosis 
and a large migrant population from highly endemic 
regions harbouring latent infection.81
Cancer and tuberculosis associations
A growing number of bacterial and parasitic infections are 
associated with development of cancer.82 Three main 
interactions have been noted between tuberculosis and 
cancer. First, tuberculosis increases lung cancer risk.83 
Second, cancers can promote reactivation of latent 
M tuberculosis infection.84 Third, immunosuppression 
attributable to cancer treatment can reactivate latent 
tuberculosis infection.85 In a com parison of 4480 Taiwanese 
adults with newly diagnosed tuberculosis and more than 
700 000 patients without tuberculosis,84 after adjustment 
for COPD and smoking-related cancers, lung cancer 
incidence was 11 times higher in people with tuberculosis. 
Signiﬁ cant risk factors were oral, nasopharyngeal, 
oesophageal, lung, and haematological cancers (eg, non-
Hodgkin lymph oma and leukaemia).
Subclinical and undiagnosed tuberculosis
One of the challenges at busy referral centres with a high 
turnover of patients, in countries highly endemic for 
tuberculosis, is that the immediate focus of the admitting 
doctor is to deal with the acute medical or obstetric 
condition that necessitated admission. Many patients 
with communicable or non-communicable diseases who 
could have concurrent active overt or subclinical 
tuberculosis are overlooked. High levels of unsuspected 
tuberculosis comorbidity with other non-communicable 
and communicable diseases have been reported among 
general internal medicine inpatients. In a study from 
Zambia,44 all patients who could produce a sputum 
sample were tested for tuber culosis, irrespective of their 
reason for admission. The presence of unsuspected active 
pulmonary tuberculosis indicated a large number of 
undiagnosed cases in the community. Tuberculosis 
screening services are needed at all points of care for non-
communicable and com municable diseases.
Maternal and child health and tuberculosis 
Several maternal illnesses and lifestyle factors during 
pregnancy (eg, smoking, malnutrition, substance mis-
use) can aﬀ ect the health of an unborn child and 
contribute to poor intrauterine growth and low birth-
weight, subsequently increasing the risk of non-
communicable disease in adulthood. Babies born to 
malnourished or anaemic mothers are at increased risk 
of perinatal death and are likely to have higher rates of 
metabolic disease in adulthood. The in-utero and 
nutritional environment is important because it 
establishes susceptibility to metabolic diseases in later 
life. Intrauterine growth restriction followed by 
accelerated postnatal growth is associated with obesity, 
type 2 diabetes, and other features of the metabolic 
syndrome.86
Pregnant women and young children are more 
susceptible to development of active tuberculosis than 
other groups.87 At all levels of health care in sub-Saharan 
Africa, diagnosis of tuberculosis in women is easily 
overlooked. Furthermore, the low sensitivity of sputum 
smear microscopy and the time and infrastructure 
constraints of mycobacterial culture mean that not all 
tuberculosis cases are identiﬁ ed. In sub-Saharan Africa, 
tuberculosis causes 15–34% of non-obstetric maternal 
deaths.88–90 Maternal and childhood tuberculosis are 
linked epidemio logically.91–93 In HIV-infected women, 
maternal tuber culosis was linked independently to 
increased risk of mother-to-child-transmission of HIV. 
Risk of culture-conﬁ rmed tuberculosis is more than 
20-fold higher in HIV-infected versus HIV-uninfected 
infants94 living in tuberculosis-endemic areas.
In paediatric autopsy studies,24,95 tuberculosis was a 
major cause of death, although comorbidity with other 
lung infections was common. Tuberculosis can be easily 
over looked in women, particularly those who are HIV-
infected, who access routine maternal and child health 
services, because non-speciﬁ c tuberculosis symp toms 
such as fatigue or night sweats are common in pregnancy, 
childbirth, and postnatally.87 Antenatal and postnatal 
clinics should screen mothers and children for relevant 
communicable and non-communicable diseases.
Other associations between tuberculosis and 
disease
Links between cytomegalovirus, Chlamydia pneu monia, 
M tuberculosis, and non-communicable diseases such as 
coronary artery atherosclerosis and diabetes have been 
studied and debated intensively.96,97 Although tuberculosis 
has been linked to coronary artery atherosclerosis and 
acute myocardial infarction,98 a causative link has yet to 
be established. Blood-borne and sexually transmitted 
infections, including viral hepatitis, are relevant to 
tuberculosis risk, since aﬀ ected patients could also have 
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HIV or latent M tuberculosis infection. Integrated models 
of care for tuberculosis, HIV, and sexually transmitted 
infections have particular relevance in settings in which 
overlapping disease burdens aﬀ ect the same sexually 
active population.99 Guidelines for prevention and control 
of tuberculosis, HIV infection, viral hepatitis, and 
sexually transmitted infections, and for people using 
illicit drugs, are available.99–101
Despite a striking decline in recent years, malaria 
remains a major cause of chronic anaemia in tropical areas, 
particularly aﬀ ecting young children and pregnant women. 
Diabetes mellitus in adulthood has also been associated 
with an increased risk of malaria.102 Induction of the hepatic 
cytochrome P450 enzyme system by rifampicin results in a 
halving of the concentrations in serum of artemisinin and 
its derivatives, complicating the concurrent management 
of tuberculosis and acute malaria.103 
Leprosy can present as multisystem illness at any non-
communicable disease clinic.104 It remains a major 
challenge in isolated pockets within the Asia-Paciﬁ c, 
Africa, and South America regions. Although control 
eﬀ orts are combined in many countries, programme 
integration is rarely optimised. Active house-to-house 
case-ﬁ nding eﬀ orts to identify minimally symptomatic 
leprosy patients in some Paciﬁ c island nations presents 
an opportunity for expanded interventions, including 
child hood immunisation eﬀ orts and screening for tuber-
culosis, diabetes mellitus, and hypertension.
Data from the 1918 inﬂ uenza epidemic show a clear 
association between increased risk for tuberculosis-
related disease and death during this period.105 Inﬂ uenza 
and other acute respiratory infections are likely to 
augment vulnerability to tuberculosis106 and could partly 
account for some of the seasonal variability noted in 
temperate regions. Findings of a randomised controlled 
trial to assess the eﬀ ect of pneumococcal vaccination 
showed decreased rates of culture-conﬁ rmed and 
clinically diagnosed tuberculosis in vaccinated children, 
indicating the intriguing possibility that pneumococcal 
coinfection might increase children’s vulnerability to 
develop active tuberculosis.107
Community vulnerability
More than 90% of immune-competent individuals who 
acquire M tuberculosis infection never progress to active 
tuberculosis,23 indicating a high level of herd immunity 
(ﬁ gure 2). Control eﬀ orts focus mainly on early 
identiﬁ cation, isolation, and treatment of active disease 
as a means of interrupting the transmission cycle. 
Although this work makes an important contribution to 
reduce transmission within communities, it has been 
inadequate to eliminate the continuing epidemic.108,109
Tuberculosis provides a barometer of poverty and 
deprivation, since its incidence is driven by socioeconomic 
factors, poor access to and delivery of health services, 
inconsistent treatment practices, HIV, and migration 
from countries that are highly endemic for tuberculosis. 
In the WHO European region, researchers investigated 
the prospective association of a nation’s wealth, level of 
egalitarianism, migration rate, health-related lifestyle, 
and social capital with tuber culosis incidence and 
prevalence over a 10-year period (2000–09).110 Nearly 50% 
of tuberculosis variation was accounted for by a nation’s 
wealth and level of egalitarianism. National income 
levels per person and income inequality are important 
predictors for tuber culosis incidence and prevalence in 
the WHO European region.111
How can vulnerability be reduced at the population 
level? Development of an eﬀ ective vaccine is proving 
especially challenging in view of the ﬁ ne immune balance 
that is needed to contain M tuberculosis infec tion.63,64 A 
complementary strategy would be to reduce factors that 
increase vulnerability at the community level, such as 
malnutrition, cigarette smoking, indoor air pollution, 
diabetes mellitus, HIV-related immune compromise, and 
alcohol misuse (ﬁ gure 2).112,113
Tuberculosis and social determinants of health
Calls for unconventional approaches to control tuber-
culosis are not new.114 Biomedical approaches to curing 
tuberculosis, which fail to account for social 
circumstances that predispose people to disease, will 
have limited eﬀ ect. More recently, a shift has taken place 
in the policy discourse towards a social determinants 
model of health,111–115 which recognises that health 
inequalities arise directly from the unequal distribution 
of resources at a global, national, and local level115 and are 
shaped by the social structures and economic 
Figure 2: Determinants of community exposure and vulnerability that 
sustain the tuberculosis epidemic
*Optimum control interventions for tuberculosis should achieve reductions in 
community exposure and vulnerability.
Community exposure
“Infection pressure”
Community vulnerability
“Natural herd immunity”
Sustained tuberculosis epidemic* 
1) Number of infectious 
tuberculosis cases
2) Duration of infectiousness
• Undiagnosed cases
• Subclinical cases
• Delayed diagnosis
• Delayed treatment
• Ineﬀective treatment
• Drug resistance
3) Proximity of contact
• Crowding
• Poor ventilation
• High-risk  gatherings
4) Population movement
• Congregate settings (prisons 
 and mines)
• Movement of people from areas 
 endemic for tuberculosis
• Conﬂict, natural disasters
1) Immune compromise
• Malnutrition
• Diabetes 
• Alcohol and substance misuse
• Untreated HIV infection
• Extremes of age
2) Reduced local defences
• Silicoses
• Cigarette smoking
• Chronic lung disease
• Solid fuel exposure
• Total burden of lung disease
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environments in which people are “born, grow, live, 
work, and age”.116 This observation is especially apparent 
with respect to diﬀ erences in life expectancy, as high as 
29 years between countries across the world (eg, 
Botswana and Japan)117 and 17 years between the richest 
and poorest parts of London, UK.118 These diﬀ erences 
cannot be attributed to biology alone. Susceptibility to 
disease and the ability to access health care and sustain a 
course of treatment is also related to inequalities of 
wealth, power, and status, and yet many public health 
interventions aim to address individual lifestyle factors 
rather than the underlying causes of health inequalities.
Accessible health care is an important aspect of 
tuberculosis case-ﬁ nding, yet the inverse care law119 
suggests the availability of good health care is inversely 
related to the needs of the population served. If people in 
greatest need are less likely to access appropriate health 
care, this factor will have important implications for the 
organisation and delivery of tuberculosis services for 
socially and economically marginalised populations. At 
an operational level, responsive outreach services 
delivered at scale and integrated into existing health 
systems, with the ability to address the health and social 
care needs of speciﬁ c populations in distinct contexts, 
are likely to entail mixed economies of care,108 which 
might raise concerns about fragmentation of services.
Although integrated delivery of care for communicable 
and non-communicable diseases has several advantages, 
evidence is scanty for its eﬀ ectiveness120 and how best to 
achieve it.121 Vertical service delivery models target very 
speciﬁ c health outcomes, frequently diverting resources 
away from comprehensive primary care services that are 
already constrained. Adopting a so-called diagonal 
approach to scaling up primary women-centred health 
care—since many diseases aﬀ ecting women are 
interrelated—has been suggested.122 Service conﬁ gur-
ations based on MDGs 4, 5, and 6 (actions on maternal 
and child mor tality, HIV, malaria, and tuberculosis) 
could incorporate services for non-communicable 
diseases (heart disease, obesity, smoking, diabetes, 
Public health and advocacy campaigns
• Reduce poverty and deprivation
• Promote healthy living
• Reduce cigarette smoking (tobacco control), solid fuel use
• Reduce excessive alcohol use and substance misuse
• Improve health literacy
Maternal and child health initiatives and services
Antenatal and obstetric services
• Routine screening for HIV, tuberculosis, malaria (in endemic 
areas), diabetes mellitus, and hypertension
• Routine screening for sexually transmitted infections
• Administration of BCG vaccination to neonates
Child health
• Routine administration of the expanded programme of 
immunisation, with vaccines for hepatitis B, 
Haemophilus inﬂ uenzae type B, pneumococcus, rotavirus, 
and human papillomavirus
• Regular monitoring and mapping of weight gain on a 
Road to Health chart
• Inclusion of paediatric tuberculosis in integrated 
management of childhood illness approaches
• Regular deworming
Tuberculosis and HIV services
Joint services
• Family clinics for family diseases
• Optimised infection control
Pragmatic screening and active case-ﬁ nding strategies
• HIV patients regularly screened for tuberculosis, and all 
patients with tuberculosis tested routinely for HIV infection, 
particularly when HIV prevalence exceeds 1%
• Screening package to include weight and growth 
monitoring, blood pressure, blood sugar or HbA1c, and 
cholesterol if indicated
Tuberculosis and diabetes mellitus programmes
Pragmatic screening and active case-ﬁ nding strategies
• All patients with diabetes mellitus screened regularly for 
tuberculosis, and patients with tuberculosis tested routinely 
for diabetes mellitus (random glucose of HbA1c), particularly 
in highly prevalent areas
Enhanced disease control
• Shared treatment supervision (eg, directly observed 
treatment for diabetes and tuberculosis)
Tuberculosis, smoking cessation, and chronic respiratory 
care
• Linking smokers diagnosed with tuberculosis to smoking 
cessation programmes
• Linking tuberculosis patients with chronic lung disease to 
ongoing respiratory care
• Supporting and enhancing existing practical approach to 
lung health (PAL) projects
• Regular screening for tuberculosis in smokers and people 
with chronic obstructive pulmonary disease (especially in 
tuberculosis-endemic areas)
Tuberculosis and care programmes for alcohol or substance 
misuse
• Screening for harmful drinking and alcohol misuse in 
tuberculosis patients
• Linking tuberculosis patients with problems of substance or 
alcohol misuse to outreach and other care programmes
• Increasing tuberculosis risk awareness and symptom 
identiﬁ cation in substance misus e programmes
Panel 3: Priorities for integration of interventions for communicable and non-communicable diseases
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cancer), which are the leading causes of death in women 
aged 15–44 years. However, services organised around 
maternal health could disadvantage older people and 
women of non-child-bearing age and those with speciﬁ c 
non-com municable diseases.
Models of service provision, which oﬀ er outreach and 
social support through networks of formal health, social 
care, and third-sector organisations coordinated by 
outreach and link working staﬀ , have proved popular 
when clinical caseloads comprise patients with complex 
health and social care needs, including homelessness 
and substance and alcohol misuse in high-income 
settings.123 Evidence supports use of mobile radiography 
in combination with models of care that aim to ameliorate 
the social risk factors associated with non-adherence to 
treatment.124 Such models can be provided as a centralised 
service, working across areas or integrated into individual 
tuberculosis clinics. A more contextualised approach to 
risk management and targeting of resources might be 
needed. Study ﬁ ndings on the adverse health outcomes 
of crisis populations125 suggest a need to attend to the 
type of risk environments126 that contribute to excess risk 
of tuberculosis, such as overcrowding in urban 
environments, poor nutrition, previous health status 
before displacement, and dis persed populations, all of 
which make identiﬁ cation, monitoring, and treatment of 
tuberculosis and other associated communicable and 
non-communicable diseases diﬃ  cult. A lack of speciﬁ city 
can serve to homogenise risk based on group identity 
(eg, asylum seekers) and to stigmatise those very groups.
Action across the social gradient, which is propor-
tionate to the level of disadvantage, is needed for both 
preventative and curative services.112 In relation to non-
communicable diseases, perspective is needed that links 
the eﬀ ect of early lifestyle experiences on later adult life 
and highlights the cumulative eﬀ ects of disadvantage 
throughout life. Thus, structural interventions are 
needed outside formal health-care sectors,127 such as 
programmes for urban regeneration, job creation, and 
social protection initiatives. In this current climate of 
austerity, ﬁ nding ways to fund such initiatives in 
countries of low income and with a high disease burden 
is diﬃ  cult, particularly when substantial political 
commitment and redistri bution of resources is needed. 
Although health services remain largely focused on 
curative services, further investment in eﬀ ective pre-
vention measures remains important because these will 
be more cost eﬀ ective in the long run.
Conclusions
In the current poor global economic climate, we must 
avoid destructive competition between communicable 
and non-communicable diseases for the limited funds 
available for health services. Integrated solutions should 
seek to unlock potential commonalities and synergies 
and optimise scarce resources. Eﬃ  cient integration of 
tuberculosis services with those for non-communicable 
and other communicable diseases should be a priority 
(panel 3) while maintaining some vertical elements to 
secure essential functions, such as drug supply, moni-
toring and assessment, and national surveillance, to a 
point at which a small central team could oversee the 
national tuberculosis programme. Appropriate balance 
should be realised, based on the best solution in a 
particular situation, and should not be an issue of 
integration or not, or horizontal versus vertical. Focus 
on local ownership is especially important, as is 
increasing equitable domestic investment in universal 
health coverage and sustainable health services. Rates of 
tuberculosis are a useful indication of socioeconomic 
inequality and deprivation. Meeting the social and 
medical care needs of vulnerable com munities needs a 
cohesive response from many groups, including the 
private sector.128
Prevention and management of chronic communicable 
and non-communicable diseases is a litmus test for health-
systems strengthening.120 Integrated strategies should be 
designed to build capacity and encourage local ownership 
to develop contextualised solutions to key health challenges 
(panel 3). The need for continued and increased funding is 
greater than ever before. Countries of low and middle 
income need to augment international political and 
ﬁ nancial commitment to tackle these global health issues 
with increased mobilisation of domestic resources.
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